• Booth: 3745

Booth Profile

To overcome mouse limitations with poor immunogenic antigens, SYnAbs has developed unique rat and guinea pig monoclonal antibodies of extreme specificity and exceptional affinity. SYnAbs works on fee-for-service business model for custom mAb generation, manufacturing and development of innovative immuno-assays and has also developed off-the-shelf products of high quality (MYStick isotyping kit, primary and secondary antibodies, affinity columns...).

 Press Releases

  • SYnAbs Mouse Immunoglobulin Easy Isotyping Kit or a.k.a. "MYstik™" provides a rapid and easy method (DOT technology) to characterize mouse monoclonal antibody isotypes in cell culture supernatants or purified antibodies preparations. This Plug&Play kit includes ready-to-use reagents necessary to analyze 24 samples in less than 1h30. Buffer solutions are color coded in order to simplify pipetting steps.

    The method is based upon robust EIA enzyme immunoassay technique:  SYnAbs unique rat anti-mouse monoclonals are highly specific to each of the common light and heavy chains of mouse species and can discrimate between IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, IgE, kappa chain and lambda chain. Samples are placed on the strip without any predilution. If desired isotype mAb is present, it will bind to rat mAb by affinity. Note that only specific mAb and none the irrelevant molecules will bind. That counts for the specificity of the test. Second mAb is then added, this one conjugated with enzyme. Colorgenic enzyme substrate is added. The interaction between substrate and captured enzyme generates visible color or dot.

  • Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some companies have developed fusion cell lines to generate monoclonal antibodies in rabbit (Abcam-Epitomics) or in sheep (Bioventix). However, these two tools are not totally satisfactory whether in terms of cost, stability or productivity.

    SynAbs has therefore opted to develop its own myeloma cell line to manufacture guinea pig monoclonal antibodies and offer more efficient investigation tools for researchers.

  • Antibodies have become a cornerstone of modern research and in vitro diagnostics, generating yearly revenues close to 2 billion dollars. Most of these are produced in mice, despite some significant intrinsic limitations of mouse antibodies. Belgian spin-off company SynAbs now presents a highly interesting alternative: rat antibodies. By shifting from mouse antibodies to rat antibodies, many new advantages can be exploited to make antibody technology even better.

  • SynAbs is proud to announce strategic deal with successful company Singapore Advanced Biologics.

    SABio is a Singapore-based producer and distributor of custom biologics such as RNA oligos, secondary antibodies, transfection reagents and peptides. SYnAbs monoclonal antibodies catalogue, composed of unique rat and guinea pig secondary mAbs, is perfectly complementary to SABio's mouse monoclonal antibodies expertise.

    Under the terms of the agreement, SABio will have access to unique portfolio of rats and guinea pigs mAbs to address Singapore territories needs in R&D and IVD fields.

    Choonjoo Kho - Chief Executive Officer SABio

    Innovation Centre Block 1, Unit 103,

    16 Nanyang Drive, Singapore 637722

  • Numbers speak for themselves : 83% of the 63 evaluable children who received tisagenlecleucel in phase 2 trial had complete elimination of malignant cells in just 3 months, while no other therapeutic option are available.

    For those of you living on the moon for the last 5 years, this is the « miracle cure » of cancer : CAR-T adoptive cell therapy. The approval of Novartis’ Kymriah made headlines in August this year as the first gene-edited cell therapy for cancer to be approved by FDA. Probably the first of a long series.

    RD-Biotech/SynAbs/Diaclone association has recently entered the field by providing a unique one-stop-shop solution for biotech players developing the mentioned approach.

    RD Biotech starts with the expression of recombinant cancer antigen in order to specifically generate the adequate mouse monoclonal antibody against it. Thanks to molecular platform, the sequencing of VH and VL regions of this last structure allows us to create an extracellular single-chain variable fragment (scFv), first component of Chimeric antigen receptors, or CARs.

     Following the collection of a patient's T cells by leukapheresis, the cells are genetically engineered by RD-Biotech through inactivated lentivirus particles containing the coding sequence for the CAR. In fact, lentivirus are used for the transfection of activated T cells, introducing the complete pattern of CAR : scFv derived from an antibody, joined to a spacer peptide and a transmembrane domain, which is further linked to the intracellular T cell signaling domains of the T cell receptor : CAR T cells have just been born right before our eyes !

    To ensure that the CAR-T cell is well activated, Diaclone launches its specific interferon gamma ELISpot test assay attesting that the CAR-T combines the specificity of an antibody for CD proteins, with the cytotoxic and memory functions of T cells.

    Since we’re speaking of a mouse ScFv, the use of the rat as a host animal allows better immunization and thereby greater diversity of monoclonal antibodies against regions that would not be immunogenic if the mouse was used. Drawing on its expertise in secondary monoclonal antibodies, SynAbs is now part of cell therapy game by generating rat monoclonal antibodies against mouse CAR-T.

    Thanks to this new available tool, our partners are now able to select specific transfected CAR-T populations on flow cytometry platform !

     Regarding therapeutic applications, RD-Biotech will then loop the loop, offering to its worldwide customers its expertise to humanize the generated ScFv, providing a better tolerance of the CAR-T for human body meanwhile maintaining the high functionality provided by the rat immune repertoire !

    The best of both worlds for better antibodies tools in cell therapy!

 Additional Info

Included in the Export Interest Directory?
Business Needs:
Direct Sales, Distributor/Agent/Representative
Products to be exported:
MYStik Mouse isotyping kit ; Secondary monoclonal antibodies